Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Temporal and geographic variation in the systemic treatment of advanced prostate cancer

Fig. 1

Title. Rates of Therapy Use. The top panel shows administration rates of the different therapies over years 2010 through mid-2015, defined as the proportion of patients who received that drug at some point in that year out of all patients who received any of those drugs that year. Rates were calculated for each drug for each year. The bottom panel shows administration rates of first-line therapy among the same cohort of patients, defined as the proportion of patients who received the drug as first-line therapy out of all patients who received a drug in that year. Administration rates of first-line therapy should sum to 100% in each year. The timeline below the two plots illustrates the approximate date at which each treatment was first approved for use in metastatic castration-resistant prostate cancer by the Food and Drug Administration (FDA). Docetaxel was approved in 2004 which is earlier than the timeline can demonstrate, but the other five treatments have a mark at the approximate point in time they were first approved

Back to article page
\